Evidence map›Paper›PMID 41062570›Full record

ArticleScientific reports2025

Targeted design, synthesis, molecular dynamics, ADME and in -vitro anticancer assessment of oxo-tetrahydro-pyrimidin-benzenesulfonamide hybrids as potential BRAF

Ankit Kumar Singh, Adarsh Kumar, Harshwardhan Singh, Prateek Pathak, Amita Verma, Habibullah Khalilullah, Mariusz Jaremko, Abdul-Hamid Emwas, Jurica Novak, Pradeep Kumar

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ankit Kumar SinghDepartment of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Ghudda, Bathinda, 151401, India.
Adarsh KumarDepartment of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Ghudda, Bathinda, 151401, India.
Harshwardhan SinghDepartment of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Ghudda, Bathinda, 151401, India.
Prateek PathakDepartment of Pharmaceutical Analysis, Quality Assurance and Pharmaceutical Chemistry, School of Pharmacy, GITAM (Deemed to be University), Hyderabad Campus, Visakhapatnam, India.
Amita VermaBioorganic and Medicinal Chemistry Research Laboratory, Department of Pharmaceutical Sciences, Sam Higginbottom University of Agriculture, Technology and Sciences, Prayagraj, 211007, India.
Habibullah KhalilullahDepartment of Pharmaceutical Chemistry and Pharmacognosy, College of Pharmacy, Qassim University, Unayzah, Saudi Arabia.
Mariusz JaremkoSmart-Health Initiative (SHI) and Red Sea Research Center (RSRC), Division of Biological and Environmental Sciences and Engineering (BESE), King Abdullah University of Science and Technology (KAUST), Thuwal, 23955-6900, Saudi Arabia.
Abdul-Hamid EmwasCore Labs, King Abdullah University of Science and Technology (KAUST), Thuwal, 23955-6900, Saudi Arabia.
Jurica NovakCenter for Informatics and Computing, Ruđer Bošković Institute, Zagreb, 10000, Croatia. jnovak@irb.hr.
Pradeep KumarDepartment of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Ghudda, Bathinda, 151401, India. pradeep.kumar@cup.edu.in.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BRAF mutations appear to varying degrees in human cancers. Proposed oxo-tetrahydro-pyrimidin-benzenesulfonamide hybrids target [αC-OUT/DFG-IN] conformation of BRAF

Indexed as

Antineoplastic AgentsProtein Kinase InhibitorsProto-Oncogene Proteins B-rafPyrimidinesSulfonamidesBenzenesulfonamidesCell Line, TumorCell ProliferationDrug DesignHumansMolecular Docking SimulationMolecular Dynamics SimulationSorafenibAntineoplastic AgentsBenzenesulfonamidesBRAF protein, humanProtein Kinase InhibitorsProto-Oncogene Proteins B-rafPyrimidinesSorafenibSulfonamidesAnticancerBRAFV600EComputationalMolecular dynamicsPyrimidin-benzenesulfonamideUrea

Identifiers

PMID41062570
PMCPMC12508044

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.